Drug Trial News

RSS

Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001, the company's product candidate for the treatment of a genetically-defined sub-population of patients with frontotemporal dementia.

19 Sep 2018

AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections

AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.

19 Sep 2018

Novel clinical trial to examine cannabis as potential treatment for essential tremor

Researchers at University of California School of Medicine are preparing to launch a novel clinical trial to examine the safety, efficacy and pharmacological properties of cannabis as a potential treatment for adults with essential tremor.

18 Sep 2018

Investigational nasal influenza vaccine tested in children and teens

An early-stage clinical trial testing the safety and immune-stimulating ability of an experimental nasal influenza vaccine in healthy 9- to 17-year-old children and teens has begun enrolling participants at a Vaccine and Treatment Evaluation Unit site at Saint Louis University, St. Louis, Missouri.

17 Sep 2018

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy, and tolerability of Ofev (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF).

17 Sep 2018

Boehringer Ingelheim announces study results of COPD patients treated with Spiolto Respimat

Boehringer Ingelheim announced results from the OTIVACTO study, an observational European real-world study of 7,443 Chronic Obstructive Pulmonary Disease patients treated with Spiolto Respimat, which were presented today at the European Respiratory Society International Congress 2018 in Paris, France

17 Sep 2018

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved AJOVY injection for the preventive treatment of migraine in adults.

17 Sep 2018

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

Rush University Medical Center is part of a new clinical trial testing whether an experimental vaccine can help patients' immune systems stop the spread of glioblastoma -- an aggressive form of brain cancer with veryhttps://www.rush.edu/news/press-releases/rush-testing-new-brain-cancer-vaccine few current treatment options.

14 Sep 2018

Clinical trial begins to find better treatment for chronic cases of PKDL in Africa

A clinical trial to find a better treatment for severe or chronic cases of post kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan.

12 Sep 2018

Mycovia initiates two Phase 3 clinical trials to evaluate VT-1161 in patients with RVVC

Mycovia Pharmaceuticals, making its official debut as a company developing therapies in women's health and dermatology, today announced the initiation of two Phase 3 clinical trials called VIOLET to evaluate the safety and efficacy of its lead candidate, VT-1161, in patients with recurrent vulvovaginal candidiasis

6 Sep 2018

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem, Inc., operating as Verastem Oncology, a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced dosing of the first patient in a multicenter Phase I/II clinical trial at the Dana-Farber/Harvard Cancer Center of duvelisib in combination with venetoclax in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

6 Sep 2018

Phase 1 clinical trial examining topical cream plus influenza vaccine is underway

A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a "pre-pandemic" influenza vaccine is underway at Baylor College of Medicine in Houston.

6 Sep 2018

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Recently published results of a phase 2 clinical trial have shown the best outcomes to date for newly diagnosed older Hodgkin lymphoma patients treated with brentuximab vedotin given before and after doxorubicin, vinblastine and dacarbazine chemotherapy, which is the standard of care.

5 Sep 2018

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Arrowhead Pharmaceuticals Inc. today announced that it has completed dosing of a Phase 1 clinical study of ARO-AAT, the company's second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.

31 Aug 2018

Almost half of total funding for publication of clinical trials is not disclosed, finds research

A substantial proportion of pharmaceutical industry payments to authors of oncology clinical trials published in major scientific journals are not disclosed, new research shows. The publications focused on clinical trials that tested new cancer drugs.

31 Aug 2018

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

A $2 million phase 2 Small Business Technology Transfer grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center.

31 Aug 2018

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Pfizer Inc. announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).

30 Aug 2018

Eagle Pharmaceuticals completes enrollment of second clinical study to evaluate safety, efficacy of RYANODEX

Eagle Pharmaceuticals, Inc. today announced completion of enrollment of the Company's second clinical study to further evaluate the safety and efficacy of RYANODEX® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke, an investigational new indication for the product.

30 Aug 2018

Clinical trial: Promising drug slows brain shrinkage in progressive MS patients

A promising drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half, according to new research led by Cleveland Clinic. Very limited therapies are currently available for this disabling form of the disease.

30 Aug 2018

TB Alliance initiates SimpliciTB to test if new four-drug regimen can treat most types of tuberculosis

TB Alliance has initiated a pivotal clinical trial, SimpliciTB, that will evaluate whether a new four-drug regimen can treat most types of tuberculosis including multidrug-resistant TB more quickly and effectively than currently-available treatments.

28 Aug 2018

Drug Trial News

Alector announces initiation of Phase 1 trial of AL001 for treating frontotemporal dementia

AmpliPhi receives positive feedback from FDA for its AB-PA01 product targeting P.aeruginosa infections

Novel clinical trial to examine cannabis as potential treatment for essential tremor

Investigational nasal influenza vaccine tested in children and teens

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Boehringer Ingelheim announces study results of COPD patients treated with Spiolto Respimat

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

Clinical trial begins to find better treatment for chronic cases of PKDL in Africa

Mycovia initiates two Phase 3 clinical trials to evaluate VT-1161 in patients with RVVC

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Phase 1 clinical trial examining topical cream plus influenza vaccine is underway

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Arrowhead completes dosing of ARO-AAT Phase 1 study to treat rare genetic liver disease

Almost half of total funding for publication of clinical trials is not disclosed, finds research

Leukogene receives STTR grant to optimize compound for treatment-resistant multiple myeloma

Pfizer terminates clinical studies evaluating domagrozumab for treatment of Duchenne muscular dystrophy

Eagle Pharmaceuticals completes enrollment of second clinical study to evaluate safety, efficacy of RYANODEX

Clinical trial: Promising drug slows brain shrinkage in progressive MS patients

TB Alliance initiates SimpliciTB to test if new four-drug regimen can treat most types of tuberculosis

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News